Karen E. Parrish

1.1k citations

21 papers · 734 indexed · h-index 14

Impact in

Genetics top 5%
- Glioma Diagnosis and Treatment
Oncology top 10%
- Drug Transport and Resistance Mechanisms
- PARP inhibition in cancer therapy

Papers in ⓘ

Oncology 16
- Drug Transport and Resistance Mechanisms 5
- PARP inhibition in cancer therapy 4
- Lung Cancer Research Studies 2
Genetics 10
- Glioma Diagnosis and Treatment 10

Co-authors: William F. Elmquist (15 shared papers)Jann N. Sarkaria (15 shared papers)Rajendar K. Mittapalli (6 shared papers)Terence T. Sio (1 shared paper)Rajneet K. Oberoi (1 shared paper)Katrina K. Bakken (6 shared papers)Janice K. Laramy (5 shared papers)Sani H. Kizilbash (5 shared papers)
Journals: Molecular Cancer Therapeutics (5 papers)Journal of Pharmacology and Experimental Therapeutics (5 papers)Biopharmaceutics & Drug Disposition (2 papers)mAbs (1 paper)Scientific Reports (1 paper)
Partner nations: United States Germany Sweden

In The Last Decade

Karen E. Parrish

21 papers receiving 721 citations

Peers

Countries citing papers authored by Karen E. Parrish

Since Specialization

Citations

This map shows the geographic impact of Karen E. Parrish's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karen E. Parrish with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karen E. Parrish more than expected).

Fields of papers citing papers by Karen E. Parrish

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karen E. Parrish. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karen E. Parrish. The network helps show where Karen E. Parrish may publish in the future.

Co-authors

The 25 scholars most cited alongside Karen E. Parrish, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Karen E. Parrish Line = papers co-authored together Karen E. Parrish links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 21 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Strategies to improve delivery of anticancer drugs across the blood–brain barrier to treat glioblastoma Neuro-Oncology ·Rajneet K. Oberoi, Karen E. Parrish, Terence T. Sio, Rajendar K. Mittapalli, William F. Elmquist, Jann N. Sarkaria	2015	217
2	Efflux Transporters at the Blood-Brain Barrier Limit Delivery and Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor Palbociclib (PD-0332991) in an Orthotopic Brain Tumor Model Journal of Pharmacology and Experimental Therapeutics ·Karen E. Parrish, Jenny L. Pokorny, Rajendar K. Mittapalli, Katrina K. Bakken, Jann N. Sarkaria, William F. Elmquist	2015	75
3	Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System Molecular Cancer Therapeutics ·Karen E. Parrish, Ling Cen, J. C. Murray, David Calligaris, Sani H. Kizilbash, Rajendar K. Mittapalli, Brett L. Carlson, Mark A. Schroeder, Julieann Sludden, Alan V. Boddy, Nathalie Y.R. Agar, Nicola J. Curtin, William F. Elmquist, Jann N. Sarkaria	2015	66
4	Restricted Delivery of Talazoparib Across the Blood–Brain Barrier Limits the Sensitizing Effects of PARP Inhibition on Temozolomide Therapy in Glioblastoma Molecular Cancer Therapeutics ·Sani H. Kizilbash, Shiv K. Gupta, Kenneth Tou En Chang, Ryo Kawashima, Karen E. Parrish, Brett L. Carlson, Katrina K. Bakken, Ann C. Mladek, Mark A. Schroeder, Paul A. Decker, Gaspar J. Kitange, Yuqiao Shen, Ying Feng, Andrew A. Protter, William F. Elmquist, Jann N. Sarkaria	2017	60
5	Barriers to Effective Drug Treatment for Brain Metastases: A Multifactorial Problem in the Delivery of Precision Medicine Pharmaceutical Research ·Minjee Kim, Sani H. Kizilbash, Janice K. Laramy, Gautham Gampa, Karen E. Parrish, Jann N. Sarkaria, William F. Elmquist	2018	52
6	ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B–Driven Brainstem Glioma Model Molecular Cancer Therapeutics ·Rajendar K. Mittapalli, (unknown), Karen E. Parrish, Donna Crabtree, Kyle G. Halvorson, Guo Hu, William F. Elmquist, Oren J. Becher	2016	51
7	Discovery of Orally Active Isofuranones as Potent, Selective Inhibitors of Hematopoetic Progenitor Kinase 1 ACS Medicinal Chemistry Letters ·Andrew P. Degnan, Godwin Kumi, Christopher W. Allard, Erika Araujo, Walter L. Johnson, Kurt Zimmermann, Bradley C. Pearce, S. Sheriff, Alan Futran, Xin Li, Gregory Locke, Dan You, J. S. Morrison, Karen E. Parrish, Caitlyn Stromko, Anwar Murtaza, Jinqi Liu, Benjamin M. Johnson, Gregory D. Vite, Mark D. Wittman	2021	36
8	Pharmacokinetic Assessment of Cooperative Efflux of the Multitargeted Kinase Inhibitor Ponatinib Across the Blood-Brain Barrier Journal of Pharmacology and Experimental Therapeutics ·Janice K. Laramy, Minjee Kim, Karen E. Parrish, Jann N. Sarkaria, William F. Elmquist	2018	29
9	Heterogeneous Binding and Central Nervous System Distribution of the Multitargeted Kinase Inhibitor Ponatinib Restrict Orthotopic Efficacy in a Patient-Derived Xenograft Model of Glioblastoma Journal of Pharmacology and Experimental Therapeutics ·Janice K. Laramy, Minjee Kim, Shiv K. Gupta, Karen E. Parrish, Shuangling Zhang, Katrina K. Bakken, Brett L. Carlson, Ann C. Mladek, J. Daniel, Jann N. Sarkaria, William F. Elmquist	2017	21
10	Enhancing Brain Retention of a KIF11 Inhibitor Significantly Improves its Efficacy in a Mouse Model of Glioblastoma Scientific Reports ·Gautham Gampa, Rajappa S. Kenchappa, Afroz S. Mohammad, Karen E. Parrish, Minjee Kim, James F. Crish, Amanda Luu, Rita West, Alfredo Quinones Hinojosa, Jann N. Sarkaria, Steven S. Rosenfeld, William F. Elmquist	2020	21
11	In vitroandin vivocharacterization of CYP inhibition by 1‐aminobenzotriazole in rats Biopharmaceutics & Drug Disposition ·Karen E. Parrish, Jialin Mao, Jacob Chen, Allan Jaochico, Justin Q. Ly, Quynh Ho, Sophie Mukadam, Matthew Wright	2015	17
12	Brain Distribution and Active Efflux of Three panRAF Inhibitors: Considerations in the Treatment of Melanoma Brain Metastases Journal of Pharmacology and Experimental Therapeutics ·Gautham Gampa, Minjee Kim, Afroz S. Mohammad, Karen E. Parrish, Ann C. Mladek, Jann N. Sarkaria, William F. Elmquist	2019	16
13	Brain Distributional Kinetics of a Novel MDM2 Inhibitor SAR405838: Implications for Use in Brain Tumor Therapy Drug Metabolism and Disposition ·Minjee Kim, Janice K. Laramy, Gautham Gampa, Karen E. Parrish, Richard C. Brundage, Jann N. Sarkaria, William F. Elmquist	2019	15
14	Factors Influencing the Central Nervous System Distribution of a Novel Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitor GSK2126458: Implications for Overcoming Resistance with Combination Therapy for Melanoma Brain Metastases Journal of Pharmacology and Experimental Therapeutics ·Shruthi Vaidhyanathan, Brynna Wilken-Resman, Dongjun Ma, Karen E. Parrish, Rajendar K. Mittapalli, Brett L. Carlson, Jann N. Sarkaria, W. F. Elmquist	2015	15
15	Challenges in the Delivery of Therapies to Melanoma Brain Metastases Current Pharmacology Reports ·Gautham Gampa, Shruthi Vaidhyanathan, Brynna Wilken-Resman, Karen E. Parrish, Svetomir N. Markovic, Jann N. Sarkaria, William F. Elmquist	2016	13
16	Abstract C81: BBB efflux pump activity limits brain penetration of palbociclib (PD0332991) in glioblastoma. Molecular Cancer Therapeutics ·Karen E. Parrish, Jenny L. Pokorny, Rajendar K. Mittapalli, Katrina K. Bakken, Jann N. Sarkaria, William F. Elmquist	2013	11
17	In Vivo Efficacy of Tesevatinib in EGFR -Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling Molecular Cancer Therapeutics ·Sani H. Kizilbash, Shiv K. Gupta, Karen E. Parrish, Janice K. Laramy, Minjee Kim, Gautham Gampa, Brett L. Carlson, Katrina K. Bakken, Ann C. Mladek, Mark A. Schroeder, Paul A. Decker, William F. Elmquist, Jann N. Sarkaria	2021	10
18	Immunoaffinity microflow liquid chromatography/tandem mass spectrometry for the quantitation of PD1 and PD‐L1 in human tumor tissues Rapid Communications in Mass Spectrometry ·Yongxin Zhu, Jacob Zalaznick, Bogdan Sleczka, Karen E. Parrish, Zheng Yang, Timothy Olah, Petia Shipkova	2020	5
19	Pharmacodynamics‐based approach for efficacious human dose projection of BMS‐986260, a small molecule transforming growth factor beta receptor 1 inhibitor Biopharmaceutics & Drug Disposition ·Karen E. Parrish, Jesse Swanson, Lihong Cheng, Emily Luk, Paul Stetsko, James Smalley, Yue‐Zhong Shu, Jinwen Huang, Jonathan G. Pabalan, Yongnian Sun, Tatyana Zvyaga, Mary Ellen Cvijic, James R. Burke, R. M. Borzilleri, Anwar Murtaza, Karen A. Augustine, Zheng Yang	2020	2
20	A novel in vitro serum stability assay for antibody therapeutics incorporating internal standards mAbs ·Yihan Li, Rosendo Villafuerte-Vega, Vikram M. Shenoy, Heather Jackson, Yuting Wang, Karen E. Parrish, Gary J. Jenkins, Hetal Sarvaiya	2025	1

About Karen E. Parrish

Karen E. Parrish is a scholar working on Oncology, Genetics, Molecular Biology, Pulmonary and Respiratory Medicine and Biomaterials, having authored 21 papers that have together received 734 indexed citations. Recurring topics across this work include Glioma Diagnosis and Treatment (10 papers), Drug Transport and Resistance Mechanisms (5 papers), PARP inhibition in cancer therapy (4 papers), Melanoma and MAPK Pathways (3 papers), Brain Metastases and Treatment (3 papers), Lung Cancer Treatments and Mutations (3 papers), Nanoparticle-Based Drug Delivery (2 papers) and Lung Cancer Research Studies (2 papers). The work is most often cited by research in Genetics (276 citations), Oncology (315 citations), Biomaterials (96 citations), Neurology (52 citations) and Cancer Research (84 citations). Karen E. Parrish has collaborated with scholars based in United States, Germany and Sweden. Frequent co-authors include William F. Elmquist, Jann N. Sarkaria, Rajendar K. Mittapalli, Terence T. Sio, Rajneet K. Oberoi, Katrina K. Bakken, Janice K. Laramy, Sani H. Kizilbash, Gautham Gampa and Minjee Kim. Their work appears in journals such as Molecular Cancer Therapeutics, Journal of Pharmacology and Experimental Therapeutics, Biopharmaceutics & Drug Disposition, mAbs and Scientific Reports.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact